We report results of in-vivo light dosimetry of light fluence (rate) in human prostate during photodynamic therapy (PDT). Measurements were made in-vivo at the treatment wavelength (732nm) in 15 patients in three to four quadrants using isotropic detectors placed inside catheters inserted into the prostate. The catheter positions are determined using a transrectal ultrasound (TRUS) unit attached to a rigid template with 0.5-cm resolution. Cylindrical diffusing fibers with various lengths are introduced into the catheters to cover the entire prostate gland. For the last four patients, distributions of light fluence rate along catheters were also measured using a computer controlled step motor system to move multiple detectors to different distances (with 0.1 mm resolution). To predict the light fluence rate distribution, a kernel-based model was used to calculate light fluence rate using either (a) the mean optical properties (assuming homogeneous optical properties) for all patients or (b) using distributions of optical properties measured for latter patients. Standard deviations observed between the calculations and measurements were 56% and 34% for (a) and (b), respectively. The study shows that due to heterogeneity of optical properties significant variations of light fluence rate were observed both intra and inter prostates. However, if one assume a mean optical properties (µ a = 0.3 cm -1 , µ s ' = 14 cm -1 ), one can predict the light fluence rate to within a maximum error 200% for 80% of the cases and a mean error of 105%. To improve the prediction of light fluence rate further would require determination of distribution of optical properties.
I. INTRODUCTION
Photodynamic therapy (PDT) is a treatment modality employing light of an appropriate wavelength in the presence of oxygen to activate a photosensitizing drug which then causes localized cell death or tissue necrosis. Using a surface illumination technique, PDT has been used to treat many superficial tumors including skin, lung, esophagus, and bladder (1) . This technique is, however, inadequate when applied to large bulky tumors or solid organs due to limited light penetration into tissue. A more efficient illumination scheme would be interstitial light delivery whereby optical fibers are placed directly into the bulky tumors or organs.
The prostate gland is an organ that appears to be a good target for interstitial PDT. Tumors of the prostate are often confined to the prostate itself and brachytherapy techniques used for the placement of radioactive seed implants can be adapted for the placement of interstitial optical fibers (2) . Several preclinical studies have evaluated the feasibility of delivering PDT to the prostate via this interstitial approach (3) (4) (5) (6) (7) . The development of this light delivery technique has necessitated an improved understanding of light dosimetry, critical in planning the configuration of multiple fibers within the organ or tumor. Based on results of a preclinical study in canine (8) , we have initiated a motexafin lutetium (MLu)-mediated PDT of the prostate in human at University of Pennsylvania. (9) MLu is a second generation synthetic photoactive drug that has a Q-band absorption peak at 732 nm. (10) (11) Ideal optimization of the photodynamic linear light sources depends on knowledge of the spatial distributions of (1) tissue light opacity within the prostate, (2) photosensitizing drug, and (3) oxygen within tissue. Since these spatial distributions can vary in time, measurements must be done to monitor the process, and feedback mechanisms must be developed to optimize PDT dose. The most effective method of the feedback mechanism is to adjust the light source strengths to compensate for the light fluence rate variation over time. To do so, an effective method to determine the light fluence rate in threedimensions in-vivo is important.
Our study focused on the prediction of light fluence rate distribution in the human prostate during PDT. A model was developed to calculate the light fluence rate in 3D volume. The calculations and measurements were examined in 15 patients. A study of the inhomogeneous light-opacity distribution in vivo is performed and reported elsewhere. (12) (13) II. METHODS AND MATERIALS
In-vivo light fluence rate measurements in human prostate
A Phase I clinical trial of motexafin lutetium (MLu)-mediated PDT in patients with locally recurrent prostate carcinoma was initiated at the University of Pennsylvania. The protocol was approved by the Institutional Review board of the University of Pennsylvania, the Clinical Trials and Scientific Monitoring Committee (CTSRMC) of the University of Pennsylvania Cancer Center, and the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. A total of 16 patients were treated, of which 15 patients have undergone in-vivo light fluence rate measurements. Each patient who signed the informed consent document underwent an evaluation, which included an MRI of the prostate, bone scan, laboratory studies including PSA (prostatic specific antigen), and a urological evaluation. Approximately two weeks prior to the scheduled treatment a transrectal ultrasound (TRUS) was performed for treatment planning. An urologist drew the target volume (the prostate) on each slice of the ultrasound images. These images were spaced 0.5 cm apart and were scanned with the same ultrasound unit used for treatment.
A built-in template with a 0.5-cm grid projected the locations of possible light sources relative to the prostate. A treatment plan was then prepared to determine the location and length of light sources. Cylindrical diffusing fibers (CDF) with active lengths 1-5 cm were used as light sources. The sources were spaced one centimeter apart and the light power per unit length was less than or equal to 150 mW/cm 2 for all optical fibers. The length of the CDF at a particular position within the prostate was selected to cover the full length of the prostate (see Fig. 1a ). The final plan often required that the prostate be divided into four quadrants. Four isotropic detectors were used, each placed in the center of one quadrant. A fifth isotropic detector was placed in a urethral catheter to monitor the light fluence in the urethra (Fig. 1b) . The patients were anesthetized in the operating room with general anesthesia to minimize patient movement during the procedure. Transrectal ultrasound-guided biopsies for MLu measurements were obtained prior to light delivery. The ultrasound unit was used to guide needle placement in the operating room. A template was attached to the ultrasound unit and was matched to the same 5-mm grid used for treatment planning (Fig. 1b) .
Four detector catheters (one for each quadrant) were inserted into the prostate. These detectors were kept in place during the entire procedure of PDT treatment. Four additional pre-planned treatment catheters for cylindrical diffusing fiber light sources were then inserted 0.5 or 0.7 cm away from the detector catheters (Fig. 1b) . The source catheters were used for light delivery and point source measurements. A 15-W diode laser, model 730 (Diomed, Ltd., Cambridge, United Kingdom) was used as the 732 nm light source. The detector position in each quadrant was varied to obtain the peak light fluence rate within the quadrant.
Isotropic detectors with scattering tips were used for all measurements (14) . Each isotropic detector was calibrated in air in an integrating sphere right before the light fluence rate measurement with an accuracy of ±5%. A tissue correction factor of 2.0 was applied to all data to correct for detector signal reduction due to changes in index of refraction (15) .
To evaluate the distribution of light fluence rate, a point source was introduced in the prostate before and after PDT for selected patients. The distance dependence of light fluence rate was measured using a motorized isotropic detector (13) . The distance dependence was modeled using a point source model in a homogeneous and infinite medium to determine the optical properties at the location of measurement. A summary of measurements made are listed in Table 1 . 
Kernel-based 3D light fluence rate calculation in homogeneous medium
The transport scattering (µ' s ) and absorption (µ a ) coefficients characterize the scattering and absorption properties of tissue. With the diffusion approximation, the light fluence rate φ at a distance r from a point source of power, S, where s is the energy released by light per unit time per unit length, also called unit length source strength (mW/cm). 
and h is the perpendicular distance from the center of the linear fiber. ∆x is the length step of point sources and N (odd integer) is the number of equal spaced point sources used in the summation (parenthesis in Eq. (2)). The numerical value of the summation should be independent of N (or ∆x) if N is large enough. We found that accurate results of the summation can be obtained if ∆x ≤ 0.1 cm or N ≥ 25 for l = 2.5 cm. In all our calculations N = 201 was used. The two free parameters (µ a and µ s ') are inherently separable in that for a CDF with a given length: the magnitude of the fluence rate near the light source (h = 0) is determined by µ s ' only and the slope of the spatial decay of the light fluence rate is determined by µ eff only.
In theory, measurements of φ at two different distances r from the point source with known unit length source strength s and length l are sufficient to determine both µ a and µ s '. Measurements at multiple sites allow evaluating the variation of these optical characteristics within the prostate volume. Since Eq. (1) is a non-linear equation of two free parameters µ a and µ s ', we used a differential evolution algorithm developed by Storn et al (18) . We modified the algorithm to require that all parameters (µ a and µ s ') are positive (19) . The optical properties measured in 13 patients have been published elsewhere (12) . Overall µ a varied between 0.07 -1.62 cm -1 (mean 0.3±0.2 cm -1 ) and µ s ' varied between 1.1 -44 cm -1 (mean 14±11 cm -1 ). The effective attenuation coefficient µ eff varied between 0.91 -6.7 cm -1 , corresponding to an optical penetration depth (δ = 1/µ eff ) of 0.2 -1.1 cm. The mean values of µ eff and δ were 2.9±0.8 cm -1 and 0.4±0.1 cm, respectively.
The distance dependence of light fluence rate per source power, φ/S, for all point source measurements was evaluated to determine its variation. φ/S is also compared with the dose rate distribution from an I-125 isotope source using AAPM TG43 formalism (20) .
III. RESULTS AND DISCUSSIONS
Typical results of light fluence rate measured during PDT were shown in Fig. 2 . The light fluence rate usually does not change with time. In Fig. 2 , one detector position was moved during measurement, resulting in a disturbance of light fluence rate. It is clear that the mean light fluence rate various from locations to locations in the same patient, reflecting heterogeneity of optical properties in prostate. A summary of the peak fluence rate among patients in the four quadrants are listed in Table 1 . Notice that the data in Table 1 has been corrected by the detector tissue correction factor of 2.0 to account for change of detector sensitivity in different medium (15) . ).
The peak fluence rate varies by 24 times from a minimum of 26 to a maximum of 634 mW/cm 2 (see Table 1 ). The variation within a prostate at different locations was as large as the variation among prostates. We attribute these variations to heterogeneity of optical properties. Large variations of depth dependence of light fluence rate per source power (φ/S) were observed for point source measurements (Fig. 3) . The mean curve corresponds to an optical properties of µ a = 0.3 cm -1 , µ s ' = 14 cm -1 . Clearly there is a wide variation of the depth dependence of φ/S due to heterogeneities of optical properties.
The light fluence rate dependence for the mean optical properties is very similar to the dose rate depth dependence of I-125 isotope within 1 cm from the point source (Fig. 4a) . For longer distance scales, the light fluence rate drops much faster than the radiation isotope source (Fig. 4b) . Since the effective treatment range is between 0 and 1 cm, one can justify the use of a Brachytherapy treatment planning system designed for the permanent prostate implant to perform preplan for photodynamic therapy in prostate. Figure 5 compares the light fluence rate at 0.5 cm, a typical prescription point, from a point source. The mean and standard deviation of light fluence rate at 0.5 cm from a point source is 1.48 ± 1.13 cm -2 . This variation is not as large as the variation of optical properties, µ a varied between 0.07 and 1.62 cm -1 and µ s ' varied between 1.1 and 44 cm -1 . There are instances, e.g., #6, when the variation of light fluence rate within a patient is larger than the mean variation among patients.
Using the measured mean optical properties and the kernel-based fluence rate calculation, one can determine the 3D light fluence rate distribution for a specific source loading (Fig. 6) . Figure 6a shows the iso-fluence lines for the distribution for 100 J/cm 2 for a treatment time of 1353 second using CDF of the same source strength of 150 mW/cm. The peak light fluence rates at the detector locations as well as the urethra (x) were also calculated to be compared with the actual measurement. Figure 6b shows the calculated light fluence profile along the catheter (z direction) of the prostate. It is not surprising that the light fluence rate in urethra (256.6 mW/cm 2 ) is in the same order as the peak fluence rate at the prescription points (221.7 -327.8 mW/cm 2 ). We have never measured light fluence rate from urethra, probably because of the detector placement error. We compared the calculations with measurements for light fluence rate profile at the detector location in the right upper quadrant (RUQ) and right lower quadrant (RLQ) in one patient, shown in Fig. 7 . The agreement between measurement (solid line) and the calculation (dashed line) for this particular patient is quite good. There are some features for the RLQ that was not present in the calculation. This latter difference is not surprising since one expects to see heterogeneity of optical properties, which will then affect the light fluence rate distribution.
To quantify the agreement among patients, we compared the measured light fluence rate and calculation for all patients treated using either the mean optical properties or the actual mean optical properties measured for the specific quadrant before the PDT treatment (Fig. 8) . The histogram of error is shown in Fig. 9a and 9b for the mean optical properties () and the actual mean optical properties, respectively. The mean error is 105.6% using the mean optical properties and 85% using the patient specific optical properties. Most of the error falls within 200% for either the mean or the actual optical properties. The few outlying errors (e.g., 600% for patient #3 in Fig. 8b ) are believed to be due to bleeding in the prostate, which is excluded for optical properties determination. It is not surprising that we can only achieve a mean error of 85% because of the heterogeneity of optical properties in patients. To further improve the agreement between calculation and measurement, it is necessary to account the distribution of optical properties within each patient. The comparison between calculation and measurement using the measured optical properties were performed for one patient using finite-element method. Details of the calculation are described elsewhere (21) . With the optical properties accounted for, the maximum error is now reduced to 20%. Further studies are necessary to accumulate more data to improve the fluence rate calculation in heterogeneous media as well as to quantify the agreement in threedimensions. In addition, a fast kernel-based calculation algorithm is to be developed to speed up the calculation. Currently the finite-element calculation requires a typical 300 seconds to complete a calculation. 
IV. CONCLUSION
We have measured light fluence rate in-vivo at various points in human prostates during PDT. The peak light fluence rate at the prescription point varied by 24 times (26 -634 mW/cm 2 ) for the same source loading at 732 nm, thus a real-time dosimetry system is necessary to quantify the light fluence rate in vivo. We found that for the mean optical properties, the light fluence rate distribution is similar to the dose rate distribution for I-125, making it possible to make preplans using I-125 to ensure volumetric coverage of light to the prostate. We compared measurement with calculation and found that light fluence rate calculation based on the mean homogeneous optical properties can predict the light fluence rate to a mean error of 86%. When calculation is performed based on heterogeneous optical properties, this agreement improved to 20%.
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